SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095776
Filing Date
2024-08-13
Accepted
2024-08-13 08:15:18
Documents
42
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q evok-20240630.htm   iXBRL 10-Q 1037705
2 EX-3.3 evok-ex3_3.htm EX-3.3 18406
3 EX-31.1 evok-ex31_1.htm EX-31.1 13015
4 EX-31.2 evok-ex31_2.htm EX-31.2 13114
5 EX-32.1 evok-ex32_1.htm EX-32.1 8438
6 EX-32.2 evok-ex32_2.htm EX-32.2 8414
7 GRAPHIC img216182627_0.jpg GRAPHIC 195423
  Complete submission text file 0000950170-24-095776.txt   4512211

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20240630.xsd EX-101.SCH 647299
44 EXTRACTED XBRL INSTANCE DOCUMENT evok-20240630_htm.xml XML 533159
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

IRS No.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36075 | Film No.: 241198879
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)